Cyclin D1 and Chemotherapy Response

Rahmat Cahyanur, Cosphiadi Irawan

Abstract


Cyclin D1 is a protein that plays a role in the transition from the G1 to S phase of the cell cycle. Cyclin D1 expression has been found to increase in various malignancies and, in many studies, was associated with tumor growth, stage, lymph node involvement, distant metastases, and poor prognosis. Until now, studies on the association of cyclin D1 expression level with chemotherapy response have shown different results. An in-depth understanding of the cell cycle will allow doctors to develop target therapies that work when specific interventions are carried out at certain stages. Some studies reported that cyclin D1 expression was inversely related to chemotherapy response, while others showed opposite results. A significant number of studies have attempted to elucidate this ambiguous effect of cyclin D1. The suggested mechanism involves the difference of cancer cell types, the effect of chromosome instability in a few malignancies, trigger to an excessive DNA repair protein expression stimulus, and the response to DNA damage severity. The ambiguous effect of cyclin D1 towards chemotherapy was thought to arise from the difference in tumor type, chemotherapy agents used, and cell damage severity caused by cytostatics as per different research works. More in-depth research with parallel evaluation of other possible mechanisms such as DNA repair should elucidate the reason behind the inconsistent findings.

Keywords


cell cycle, chemotherapy response, cyclin D1

References


Gioacchini FM, Alicandri-Ciufelli M, Kaleci S, Magliulo G, Presutti L, Re M. The prognostic value of cyclin d1 expression in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2016 Apr;273(4):801-9.

Li Y, Barbash O, DIehl J. Regulation of the cell cycle. In: Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson C, editors. The molecular basis of cancer. Edition 4 ed. Philadelphia, PA: Saunders/Elsevier; 2015. p. 165-78.

Dhingra V, Verma J, Misra V, Srivastav S, Hasan F. Evaluation of cyclin d1 expression in head and neck squamous cell carcinoma. J Clin Diagn Res. 2017 Feb;11(2):EC01-EC4.

Akervall J, Brun E, Dictor M, Wennerberg J. Cyclin d1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck--preliminary report. Acta Oncol. 2001;40(4):505-11.

Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. Ccnd1/cyclind1 status in metastasizing bladder cancer: A prognosticator and predictor of chemotherapeutic response. Mod Pathol. 2014 Jan;27(1):87-95.

Ngo BT, Felthaus J, Hein M, Follo M, Wider D, Ihorst G, et al. Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin d1, d2, and d3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome. Leuk Lymphoma. 2010 Sep;51(9):1632-42.

Noel EE, Yeste-Velasco M, Mao X, Perry J, Kudahetti SC, Li NF, et al. The association of ccnd1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010 Jun;176(6):2607-15.

Biliran H, Jr., Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin d1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005 Aug 15;11(16):6075-86.

Rocca A, Schirone A, Maltoni R, Bravaccini S, Cecconetto L, Farolfi A, et al. Progress with palbociclib in breast cancer: Latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.

Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin d1: Normal and abnormal functions. Endocrinology. 2004 Dec;145(12):5439-47.

Qie S, Diehl JA. Cyclin d1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl). 2016 Dec;94(12):1313-26.

Li Y, Barbash O, DIehl JA. Regulation of the cell cycle. In: Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB, editors. The molecular basis of cancer. Philadeplphia: Elsevier; 2015. p. 165-78.

Boehm M, Nabel EG. Cell cycle and cell migration: New pieces to the puzzle. Circulation. 2001 Jun 19;103(24):2879-81.

Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J, et al. Ccnd1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One. 2011;6(10):e26399.

Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D'Silva N, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014 Jan;124(1):179-87.

Moreno-Galindo C, Hermsen M, Garcia-Pedrero JM, Fresno MF, Suarez C, Rodrigo JP. P27 and bcl2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol. 2014 Feb;50(2):128-34.

Irawan C, Cahyanur R, Lisnawati L, Abdullah M, Yunus RE. The difference in the cyclin d1 expression in advanced stage nasopharyngeal cancer based on treatment response: A retrospective cohort study. Acta Med Indones. 2020 Apr;52(2):147-54.

Kornmann M, Beger HG, Link KH. Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res. 2003;161:180-95.

Jirawatnotai S, Hu Y, Livingston DM, Sicinski P. Proteomic identification of a direct role for cyclin d1 in DNA damage repair. Cancer Res. 2012 Sep 1;72(17):4289-93.

Sewify EM, Afifi OA, Mosad E, Zaki AH, El Gammal SA. Cyclin d1 amplification in multiple myeloma is associated with multidrug resistance expression. Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):215-22.

Mohanty S, Tran T, Sandoval N, Mohanty A, Bedell V, Wu J, et al. Cyclin d1 promotes survival and chemoresistance by maintaining atr and chek1 signaling in tp53-deficient mantle cell lymphoma cell lines. Blood. 2014;124(21):5197-.

Sun Y, Luo D, Liao DJ. Cyclind1 protein plays different roles in modulating chemoresponses in mcf7 and mda-mb231 cells. J Carcinog. 2012;11:12.

Jirawatnotai S, Sittithumcharee G. Paradoxical roles of cyclin d1 in DNA stability. DNA Repair (Amst). 2016 Jun;42:56-62.

Richardson C, Stark JM, Ommundsen M, Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene. 2004 Jan 15;23(2):546-53.

Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, et al. Expression of cyclin d1a and d1b as predictive factors for treatment response in colorectal cancer. Br J Cancer. 2012 Nov 6;107(10):1684-91.


Full Text: PDF

DOI: 10.33371/ijoc.v15i1.782

Article Metrics

Abstract view : 28 times
PDF - 14 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.